Syndax Pharmaceuticals SNDX Proceeds From Purchase And Sale Agreement
Proceeds From Purchase And Sale Agreement at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept sndx:ProceedsFromPurchaseAndSaleAgreement.
The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's proceeds from purchase and sale agreement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's proceeds from purchase and sale agreement?
- Syndax Pharmaceuticals (SNDX) reported proceeds from purchase and sale agreement of $0 in Q4 2025.
- How has Syndax Pharmaceuticals's proceeds from purchase and sale agreement changed year-over-year?
- Syndax Pharmaceuticals's proceeds from purchase and sale agreement decreased by 100.0% year-over-year, from $85.91M to $0.
- What does proceeds from purchase and sale agreement mean?
- This represents cash inflows received from entering into agreements to sell assets or future revenue streams, such as royalty interests. It is a financing mechanism used to generate immediate capital for research and development.